Akston Biosciences Doses First Participants in Phase II Clinical Trial
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, it dosed the first set of volunteers in an open-label study of AKS-452, its protein subunit COVID-19 vaccine, as a booster.